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0032-6 impact of Clinical Syndrome Acuity on the Differential 
Response to Two Glycoproteln iib/iiia inhibitors in 
Patients Undergoing Coronary Stenting: The TARGET 
Trial 
VW. David J. Moliterno, Michel Bertrand, Franz-Joseph Neumann, Howard 
C. Herrmann, Eric R. Powers, Cindy L. Grines. David J. Cohen, Eric A. Cohen, Marc 
Cohen, Marion Piedmonte, Pete M. DiBattiste, The Cardiovascular Research 
Foundation, New York, New York, Lenox Hill Heart and Vascular Institute, New York, 
New York. 
Background. GP Ilb/llla inhibitors reduce per&procedural events and enhance out- 
comes in pts undergoing stent implantation. The relative safety and efficacy of different 
Ilb/llta agents is less wall established. Also unknown is whether the acuity of the present- 
ing clinical syndrome, which may affect the degree of platelet inhibition required or 
achieved, influences the response to different anti-platelet agents. Methods. In the TAR- 
GET trfal, 4,609 pts undergoing stenting were randomized to abciximab vs. timfiban in 
double blind fashion. Acute coronary syndromes (unstable angina or Ml) were present in 
3,025 pts (63%) and non ACS were present in 1,764 pts (37%). 
Results. The 30-day composite incidence of death, Ml or urgent TVR occurred in 6.0% 
of pts assigned to abciximab vs. 7.6% assigned to tirofiban (p&036). By 6 months 
death, MI or any TVR occurred in 14.3% vs. 14.6% of pts respectively (pzO.59). Out- 
cornea stratified by clinical syndrome appear In the table: 
Conclusions. In pts with ACS undergoing stent implantation, abciximab use compared 
to tirofiban results in lower 30 day and 6 month rates of MI, though survival is identical. In 
contrast, pts with stable coronary syndromes treated with tirofiban have excellent acute 
and late outcomes relative to ab=cirimab. These data raise important issues regarding the 
relative pharmacodynamic potency of Ilb/llla inhibition required in varying clinical scenar- 
ios, as well as having important implications for cost-effective utilization of Ilb/llla inhibi- 
tors. 
ACS Non ACS 
Abciximab Tirofiban P Abciximab Tirofiban P 
N 1,511 1,514 - 900 604 . 
Procedural success (%) 96.2 96.0 NS 96.9 96.0 NS 
Bleeding complications (%) 4.7 3.4 NS 5.1 4.0 NS 
RBC transfusion (%) 1.6 1.1 NS 1.3 1.0 NS 
Thrombccytopenia (%) 3.6 0.6 co.oo1 3.4 0.3 co.oo1 
30 day: Death (%) 0.6 0.6 NS 0.1 0.3 NS 
Ml (%) 5.6 6.5 0.004 4.9 4.2 NS 
Urgent TVR (%) 0.5 1.1 0.10 0.9 0.5 NS 
Composite (%) 6.3 9.3 0.002 5.6 4.5 NS 
6 month: Death(%) 1.3 1.3 NS 0.6 0.7 NS 
Ml (%) 7.1 9.6 0.01 5.6 5.1 NS 
Any TVR(%) 9.0 9.5 NS 6.0 5.7 NS 
Composite (%) 15.1 17.6 0.06 13.0 10.2 0.07 
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1077-I Ostlai Location of Target Lesion and Smaller Post- 
Treatment Minimal Luminai Diameter Are Predictors of 
Failure Following Sr-90 Beta Irradiation for instent 
Restenosis 
Francis 0. Alme&. David Y. Chua, Sandeep Nathan, Susie Kim, Peter M. Meyer, 
Stephen T. Thew, Jeffrey Snell, Gary L. Schaer. Rush-Presbyterian-St. Luke’s Medical 
Center, Chicago, Illinois. 
Background: lntracoronary radiation therapy (IRT) with Sr-90 has been shown to be 
effective for the treatment of instent restenosis (ISR) compared to placebo in large ran- 
domized clinical trials. However, the predictors of failure following IRT in a broad range of 
patients (pts) have not been clearly defined. 
Methods: To determine the predictors of IRT failure, we compared the baseline demo- 
graphics, lesion characteristics, and clinical outcomes of 102 consecutive pts with ISR 
treated with Sr-90 using the Novosta Beta-Cath System from Sept.1996 to July 2001. 
IRT failure was defined as death, myocardial infraction (MI), or target vessel revascular- 
ization (TVR) due to repeat ISR on follow up. 
Results: A comparison of the clinical and angiographic profile of IRT failures vs. suc- 
cesses is shown using univariate analysis (Table). Multivariate regression analysis 
showed that the predictors of failure that remained significant were treatment of an ostial 
lesion (OR 31.2, 95% Cl 2.6, 362.7, p=O.O07), and post-treatment MLD (p<O.OOl). 
Table: PredIctora of IRT Failure Uslng Unlvariate Analysis 
IRT Failure IRT Success P value 
(n.16) (n=66) 
Mean Age (yrs) 61.5+11.1 61.6zt12.4 0.704 
Male % 69 79 0.521 
Diabetes % 77 65 0.766 
Hypertension % 100 91 0.351 
Hyperlipidemia 94 93 0.916 
Smoking Hx % 75 40 0.012 
Family History of CAD % 43 35 0.367 
Prior CABG % 50 43 0.765 
Calcium Channel Blocker Use % 64 45 0.013 
SVG Lesion % 19 14 0.701 
Ostial Lesion % 44 16 0.020’ 
Mean Lesion Length (mm) 17.67fl2.2 17.27+12.5 0.324 
Mean Reference Vessel Diameter (mm) 2.96zt0.35 3.14ti.91 0.567 
Mean Pre-Treatment MLD (mm) o.tio.14 1.010.19 0.360 
Mean Post-Treatment MLD (mm) 1.64fio.19 2.21iO.29 <O.OOl’ 
‘p value remained significant (~0.05) after multivariate analysis 
Conclusion: Ostial location of the target lesion and smaller post-treatment MLD were 
predictors of subsequent death, MI and TVR following therapy with Sr-90 for ISR. Maxi- 
mizing final procedural results especially in ostial lesions may further improve outcomes 
after IRT. 
1077-2 Comparative Efficacy of Gamma-irradiation for 
Treatment of in-Stent Restenosis in Saphenous Vein 
Graft Versus Native Coronary Artery In-Stent 
Restenosis: An intravascular Ultrasound Study 
B, Gary S. Mint& Javed M. Ahmed, Neil J. Weissman, Akiko Maehara, 
Andrew E. Ajani. Lowell F. Satler, William 0. Suddath, Kenneth M. Kent, August0 D. 
Pichard. Ron Waksman, Washington Hospifal Center, Washington, Disf. of Columbia, 
Cardiovascular Reasearch Foundation, New York, New York. 
Background: We used serial (post irradiation and follow-up) volumetric intravascular 
ultrasound (IVUS) to compare the effectiveness of gamma-irradiation (‘g*lr) in saphen- 
ous vein graft (SVG) versus native coronary artery in-stent restenosis (ISR) lesions. 
Methods and Results: 47 patients with native coronary artery ISR from WRIST and 31 
patients with SVG ISR (12 from the WRIST and 19 from SVGWRIST) were compared. 
Post-irradiation and at B-month follow-up, stent, lumen, intimal hyperplasia (IH= stem 
minus lumen) areas were measured every lmm. ISR length was similar in the two 
groups (29+12 vs 29a14mm. p=O.9). Post-intervention measurements of stent (260+154 
vs 324*270mm’, p=O.4), lumen (164*91 vs 214*172mm3, p=O.3), and IH (96+77 vs 
109+119mms, p=O.5) volumes were similar in the two groups. The post-intervention min- 
imum lumen area (MLA) tended to be smaller in native artery ISR lesions (4.7~1.7 vs 
5.4*1.6mm2, p=O.il). Serial measurements are shown in the table. During follow-up, 
there was a slight increase in IH volume in native artery ISR lesions and a slight 
decrease in IH volume in SVG ISR lesions. There was a1so.a slight decrease in MLA in 
the native artery ISR lesions versus a slight increase in MLA in the SVG ISR lesions. As 
a result, the follow-up MLA in native artery lesions was smaller than in SVG ISR lesions 
(4.1e2.1 mm* versus 5.6i2.2 mm*, p=O.O067). 
Conclusion: Volumetric IVUS analysis shows that ‘921r brachytherapy appears to be as 
effective in SVG’s as it is in native artery ISR lesions. 
Changes In IVUS measurements 
Stent volume, mm3 
Lumen volume, mm3 
IH volume, mm3 
Minimum lumen area, mm’ 
Native SVG P 
-5*14 -9*30 0.4 
-14+41 -0*35 0.16 
9+3l3 -9*32 0.0463 
-0.6+1.7 0.2+1 .l 0.0067 
1077-3 Changing Pattern of in-Stent Restenosis After 
intracoronary Beta-irradiation: Downsizing the Lesion 
Christooh K. Naber, Chatchawan Suphatheeratham. Katja Brauck, Tom Oberheiden, 
Holger Eggebrecht, Yasser Abdel Rahman. Wolfgang Sauerwein, Raimund Erbel, 
Dietrich Baumgart, Cardiology, University of Essen, Essen, Germany 
Background: the treatment of diffuse recurrent stenosis after stent placement, remains a 
challenging task for the interventional cardiologist. lntracoronary radiation therapy (IRT) 
has proven to be highly effective in this indication. Nevertheless, also this novel therapy 
fails to prevent recurrent stenosis in a certain number of patients. It has been speculated, 
whether IRT may help in these cases to change the pattern of recurrent stenosis towards 
shorter and less diffuse lesions which are more suitable for the treatment with conven- 
tional interventional techniques. 
Methods and Results: 105 consecutive patients who underwent PTCA and adjuvant IRT 
for in-stent restenosis were included. Mean age was 56.1i12.2 years, 14.2% were dia- 
